103 related articles for article (PubMed ID: 8497337)
1. An increase in the in vivo binding of [3H]SCH 23390 induced by MK-801 in the mouse striatum.
Kobayashi K; Inoue O
Neuropharmacology; 1993 Apr; 32(4):341-8. PubMed ID: 8497337
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of 3H-N-methylspiperone binding but not 3H-raclopride binding in mouse striatum by MK-801: evidence that factors other than competition by endogenous dopamine are responsible for changes in D2 receptor binding in vivo. Short communication.
Inoue O; Wakahara S; Kobayashi K; Gee A
J Neural Transm (Vienna); 1999; 106(2):131-7. PubMed ID: 10226933
[TBL] [Abstract][Full Text] [Related]
3. The effect of benzodiazepines on the binding of [3H]SCH 23390 in vivo.
Inoue O; Kobayashi K; Sakiyama Y; Suzuki T
Neuropharmacology; 1992 Feb; 31(2):115-21. PubMed ID: 1313156
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of SCH 23390-induced alteration of striatal dopamine D1 receptor ontogeny by prolyl-leucyl-glycinamide in the rat.
Kostrzewa RM; Saleh MI
Neuropharmacology; 1989 Aug; 28(8):805-10. PubMed ID: 2571103
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D1 binding sites in the striatum of the mutant mouse weaver.
Ohta K; Graybiel AM; Roffler-Tarlov S
Neuroscience; 1989; 28(1):69-82. PubMed ID: 2527338
[TBL] [Abstract][Full Text] [Related]
6. Reserpine-induced reduction of in vivo binding of SCH 23390 and N-methylspiperone and its reversal by d-amphetamine.
Inoue O; Tsukada H; Yonezawa H; Suhara T; Langstrom B
Eur J Pharmacol; 1991 May; 197(2-3):143-9. PubMed ID: 1915566
[TBL] [Abstract][Full Text] [Related]
7. MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors.
Wedzony K; Klimek V; Gołembiowska K
Brain Res; 1993 Sep; 622(1-2):325-9. PubMed ID: 8242376
[TBL] [Abstract][Full Text] [Related]
8. MK-801, a non-competitive antagonist of NMDA receptor, prevents methamphetamine-induced decrease of striatal dopamine uptake sites in the rat striatum.
Muraki A; Koyama T; Nakayama M; Ohmori T; Yamashita I
Neurosci Lett; 1992 Feb; 136(1):39-42. PubMed ID: 1353257
[TBL] [Abstract][Full Text] [Related]
9. In vivo striatal binding of the D1 antagonist SCH 23390 is not modified by changes in dopaminergic transmission.
Thibaut F; Vaugeois JM; Bonnet JJ; Costentin J
Neuropharmacology; 1996 Mar; 35(3):267-72. PubMed ID: 8783200
[TBL] [Abstract][Full Text] [Related]
10. Similar pharmacological properties of 8-OH-DPAT and alnespirone (S 20499) at dopamine receptors: comparison with buspirone.
Protais P; Lesourd M; Comoy E
Eur J Pharmacol; 1998 Jul; 352(2-3):179-87. PubMed ID: 9716353
[TBL] [Abstract][Full Text] [Related]
11. Different binding affinities of NMDA receptor channel blockers in various brain regions--indication of NMDA receptor heterogeneity.
Bresink I; Danysz W; Parsons CG; Mutschler E
Neuropharmacology; 1995 May; 34(5):533-40. PubMed ID: 7566488
[TBL] [Abstract][Full Text] [Related]
12. Cortical stimulation induces Fos expression in striatal neurons via NMDA glutamate and dopamine receptors.
Liste I; Rozas G; Guerra MJ; Labandeira-Garcia JL
Brain Res; 1995 Nov; 700(1-2):1-12. PubMed ID: 8624698
[TBL] [Abstract][Full Text] [Related]
13. [3H]SCH 23390 identifies D-1 binding sites in rat striatum and other brain areas.
Kilpatrick GJ; Jenner P; Marsden CD
J Pharm Pharmacol; 1986 Dec; 38(12):907-12. PubMed ID: 2880965
[TBL] [Abstract][Full Text] [Related]
14. [Effects of antagonists of NMDA receptor on methamphetamine-induced decrease in the dopamine uptake sites in the rat striatum and on the behavioral sensitization].
Muraki A
Hokkaido Igaku Zasshi; 1993 May; 68(3):407-18. PubMed ID: 8319937
[TBL] [Abstract][Full Text] [Related]
15. Striatal D1- and D2-dopamine receptor sites are separately detectable in vivo.
Leslie CA; Bennett JP
Brain Res; 1987 Jul; 415(1):90-7. PubMed ID: 2957025
[TBL] [Abstract][Full Text] [Related]
16. Binding sites for [3H]SCH 23390 in retina: properties and possible relationship to dopamine D1-receptors mediating stimulation of adenylate cyclase.
Makman MH; Dvorkin B
Brain Res; 1986 Dec; 387(3):261-70. PubMed ID: 2950967
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic basis for the facilitation of brain stimulation reward by the NMDA receptor antagonist, MK-801.
Olds ME
Eur J Pharmacol; 1996 Jun; 306(1-3):23-32. PubMed ID: 8813611
[TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with MK-801 increases the quinolinic acid-induced loss of D-1 dopamine receptors in rat striatum.
Norman AB; Ford LM; Kolmonpunporn M; Sanberg PR
Eur J Pharmacol; 1990 Feb; 176(3):363-6. PubMed ID: 2139415
[TBL] [Abstract][Full Text] [Related]
19. Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice.
Liljequist S; Ossowska K; Grabowska-Andén M; Andén NE
Eur J Pharmacol; 1991 Mar; 195(1):55-61. PubMed ID: 1829683
[TBL] [Abstract][Full Text] [Related]
20. Anti-glutamatergic effects of clozapine.
Lidsky TI; Yablonsky-Alter E; Zuck L; Banerjee SP
Neurosci Lett; 1993 Dec; 163(2):155-8. PubMed ID: 7906022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
